Roche shares fall as new drug sales disappoint

FRANKFURT (Reuters) -Shares of Swiss drugmaker Roche fell on Thursday after sales of its new treatments for eye disease and haemophilia disappointed the market, even as its nine-month revenue broadly met expectations. Although Roche hiked its full-year forecast for adjusted earnings and has stepped up efforts to break into the fast-growing obesity market, investors are concerned that it is relying too heavily on its older blockbuster drugs.